Actuate Therapeutics, Inc. (ACTU)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.48+8.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Primary pillar under pressure — Sufficient capital to fund operations and trials: MVLS < $50M vs $50M target.
Actuate is advancing clinical trials for cancer treatments. The company raised capital through debt in 2025 to fund growth. A new board member joined in 2026, signaling strategic focus. If trials succeed, Actuate could address unmet medical needs and grow value.
Actuate is loss-making with negative EPS of -$0.78 expected in 2026. The stock has fallen 54.5% from its high. No revenue is currently expected, and clinical trial risks remain high. Capital needs and trial failures could hurt the company further.
The market prices in continued losses and no revenue growth, reflecting high risk. Our view differs by focusing on the potential upside from clinical progress and strategic hires, which are not yet reflected in estimates.
Breaks if: Capital depletion or failure to raise funds by end 2026
Breaks if: Failure to achieve key clinical milestones or negative trial results in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as ACTU is currently loss-making and navigating a high-risk environment. The long-term thesis is under pressure due to persistent cash burn and the need for additional capital.
The market appears to have priced in the ongoing losses and high risk associated with ACTU. Recent financial performance has not met expectations compared to its industry peers, suggesting that the current valuation reflects a cautious outlook.
Fundamentals are likely to remain weak in the near term, with a high probability of an earnings miss. Management's focus on advancing clinical programs and securing capital is crucial, but results are still at an early stage with no revenue yet.
The thesis hinges on several factors, including the potential for management to secure additional capital and the performance of sector leaders that could influence sentiment. Additionally, any negative guidance or worsening economic indicators could further impact ACTU's outlook.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS loss worsens beyond -$0.78 in FY26
Over the next 1 to 3 years, ACTU's situation remains precarious, with high risks and ongoing losses. Not investment advice.